(Z)-6-Methyl-3-heptene-2,5-dione | 292623-06-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (Z)-6-Methyl-3-heptene-2,5-dione
• 英文别名: (Z)-6-methylhept-3-ene-2,5-dione
• CAS: 292623-06-4
• 化学式: C₈H₁₂O₂
• 分子量: 140.182
• InChiKey: BWSZTLQPKADLGT-PLNGDYQASA-N

物化性质

• 沸点：
  235.4±23.0 °C(Predicted)
• 密度：
  0.941±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (Z)-6-Methyl-3-heptene-2,5-dione 在 臭氧 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 5.0h， 生成
  参考文献：
  名称：

  Novel Oxa-Cage Compounds: Synthesis, Structures, and the Formation Mechanism of Tetraacetal Oxa-Cages and Convex Tetraquinane Oxa-Cages

  摘要：

  Several novel tetraacetal era-cage compounds 5a-d and convex tetraquinane era-cage compounds 16a-d and 17b-d are synthesized from alkylfurans in three steps. Ozonolysis of the cis-endo-1,4-diones 3a-d in dichloromethane at -78 degrees C followed by reduction with dimethyl sulfide gives the era-cages 5a-d in high yields, respectively. The structures of these new tetraacetal era-cages are deduced from their spectral data and proven for the first time by X-ray analysis of the crystalline compound 5a. Ozonolysis of 3a-d in dichloromethane at -78 degrees C followed by treatment with triethylamine gives the convex tetraquinane era-cages 16a-d and 17b-d in 85-90% yields, respectively. The structures of these novel convex tetraquinane era-cages are finally proven by X-ray analysis of the crystalline compound 16a. Two reaction mechanisms via the common final ozonides are proposed for the formation of these two different types of era-cage compounds. The structures of the final ozonides formed by ozonolysis of the norbornene derivatives 3 are deduced to be 9 with endo stereochemistry on the basis of their spectral data and the formation of these two types of era-cages from the final ozonides. In reaction with the final ozonides, triethylamine is found to act as a base instead of a reducing agent, a different function from that of dimethyl sulfide. The synthesis of era-cages 24 and 25, which possess aromatic substituents directly on the skeleton, has also been accomplished.

  DOI：

  10.1021/jo00128a031
• 作为产物：
  描述：

  5-methyl-2-(1-methylethyl)furan 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 以82%的产率得到(Z)-6-Methyl-3-heptene-2,5-dione
  参考文献：
  名称：

  Novel Oxa-Cage Compounds: Synthesis, Structures, and the Formation Mechanism of Tetraacetal Oxa-Cages and Convex Tetraquinane Oxa-Cages

  摘要：

  Several novel tetraacetal era-cage compounds 5a-d and convex tetraquinane era-cage compounds 16a-d and 17b-d are synthesized from alkylfurans in three steps. Ozonolysis of the cis-endo-1,4-diones 3a-d in dichloromethane at -78 degrees C followed by reduction with dimethyl sulfide gives the era-cages 5a-d in high yields, respectively. The structures of these new tetraacetal era-cages are deduced from their spectral data and proven for the first time by X-ray analysis of the crystalline compound 5a. Ozonolysis of 3a-d in dichloromethane at -78 degrees C followed by treatment with triethylamine gives the convex tetraquinane era-cages 16a-d and 17b-d in 85-90% yields, respectively. The structures of these novel convex tetraquinane era-cages are finally proven by X-ray analysis of the crystalline compound 16a. Two reaction mechanisms via the common final ozonides are proposed for the formation of these two different types of era-cage compounds. The structures of the final ozonides formed by ozonolysis of the norbornene derivatives 3 are deduced to be 9 with endo stereochemistry on the basis of their spectral data and the formation of these two types of era-cages from the final ozonides. In reaction with the final ozonides, triethylamine is found to act as a base instead of a reducing agent, a different function from that of dimethyl sulfide. The synthesis of era-cages 24 and 25, which possess aromatic substituents directly on the skeleton, has also been accomplished.

  DOI：

  10.1021/jo00128a031

文献信息

• TOCOTRIENOL ESTERS
  申请人：El Sayed Khalid A.

  公开号：US20110196030A1

  公开（公告）日：2011-08-11

  Esters of tocotrienols having pharmacological activities pertinent to the treatment of breast cancer and other forms of cancer are disclosed herein. Among those compounds is (Z)-4-oxo-4-((R)-2,5,7,8-tetramethyl-2-((3E,7E)-4,8,12-trimethyltrideca-3,7,11-trienyl)chroman-6-yloxy)but-2-enoic acid. Tocotrienol esters were used to inhibit the growth and migration of +SA mammary epithelial cells and highly metastatic human breast cancer MDA-MB-231 cells respectively.

  本文披露了对治疗乳腺癌和其他形式的癌症具有药理活性的生育三烯酚酯。其中包括（Z）-4-氧代-4-（（R）-2,5,7,8-四甲基-2-（（3E,7E）-4,8,12-三甲基十三碳烯-3,7,11-三烯基）色苷-6-氧基）丁-2-烯酸。生育三烯酚酯被用于抑制+SA乳腺上皮细胞和高度转移性的人乳腺癌MDA-MB-231细胞的生长和迁移。
• USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS
  申请人：Franklin Richard

  公开号：US20120202756A1

  公开（公告）日：2012-08-09

  The present invention relates to prodrugs of a wide variety of drugs and pharmaceutical compositions containing such prodrugs. Methods for minimizing locally mediated (from within the gut lumen) adverse gastrointestinal events associated with the underivatised drug and increasing the sustainment of plasma drug levels with the aforementioned prodrugs are also provided. Thus, the present invention relates to the use of prodrugs of a wide diversity of drugs (other than opioids) to transiently inactivate them and so reduce directly, locally mediated adverse gastrointestinal (GI) side-effects normally evident after administration of the parent compound. Additionally, such prodrugs may confer improved pharmacokinetics.

  本发明涉及各种药物的前药和含有这些前药的制药组合物。还提供了一种方法，用于最小化与未衍生药物相关的局部介导（来自肠腔内）不良胃肠事件，并使用上述前药增加血浆药物水平的持续性。因此，本发明涉及使用各种药物（除阿片类药物外）的前药，以短暂地使它们失活，从而减少通常在给予原始化合物后出现的直接、局部介导的不良胃肠（GI）副作用。此外，这些前药可能提供改善的药代动力学。
• Zotto, Alessandro Del; Baratta, Walter; Verardo, Giancarlo, European Journal of Organic Chemistry, 2000, # 15, p. 2795 - 2802
  作者：Zotto, Alessandro Del、Baratta, Walter、Verardo, Giancarlo、Rigo, Pierluigi

  DOI：——

  日期：——
• Binding Inhibitors of the Beta. Transducin Repeat-Containing Protein
  申请人：Bradley Mark

  公开号：US20140315784A1

  公开（公告）日：2014-10-23

  The present invention relates to compounds which bind to Beta Trans-ducin repeat-containing protein (PTrCP), and modulate the activity of 13TrCP. In particular, the invention relates to compounds which demonstrate optimised binding to PTrCP. The invention also relates to pharmaceutical compositions comprising such compounds and the use of such compounds as medicaments, specifically for the treatment of disorders associated with aberrant protein degradation, such as cancer. The preferred binding inhibitors are peptides derived from the motive DSGXXS, e.g. DEGFWE, DDGFWD and Succinyl-EGFWE.
• INHIBITOR OF BRUTON'S TYROSINE KINASE
  申请人：Centaurus BioPharma Co., Ltd.

  公开号：US20170144986A1

  公开（公告）日：2017-05-25

  Provided are a compound represented by formula (III) or pharmaceutically acceptable salts, solvates, active metabolites, polymorphs, esters, tautomers or prodrugs thereof, pharmaceutical compositions containing the compound represented by formula (III), and the application of the pharmaceutical compositions as selective inreversible inhibitor of Bruton's tyrosine kinase for the prevention and treatment of inflammation, autoimmune diseases (such as rheumatoid arthritis) associated with aberrant B cell proliferation and cancers.